Intelligent Bio Solutions Inc. (INBS) Stock Score, Valuation & Financial Research
Intelligent Bio Solutions Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for INBS
Intelligent Bio Solutions Inc. currently has a Wall Street Score of 25/100. The stored market price is $2.13. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Intelligent Bio Solutions Inc. does
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in O
INBS financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $2.13
- Market capitalization:
- $1.4M
- Revenue:
- $3.9M
- Net income:
- $-11.6M
- Free cash flow:
- $-9.9M
- Cash:
- $6.9M
- Total debt:
- $1.8M
- EPS:
- -20.00
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 59/100
What stands out
- Reported year-over-year revenue growth is +0.3%.
- Free cash flow is $-9.9M, showing cash burn in the current stored period.
- The balance sheet shows $6.9M of cash versus $1.8M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research INBS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.